Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00331006 · ClinicalTrials.gov registry record · Phase 2
Rituximab to Treat Severe Hemophilia A
A Phase 2 study, sponsored by Carelon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00331006 is a Phase 2 study that has completed, run by Carelon Research. The registered enrollment target is 23 participants.
The verdict
NCT00331006, a Phase 2 study, has completed, sponsored by Carelon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Hemophilia A is a serious blood clotting disorder caused by a lack of factor VIII, a specialized protein needed for normal blood clotting to occur. Individuals with this disease may experience spontaneous bleeding, pain and swelling in their joints due to excess bleeding, and bruising. A common treatment for severe hemophilia A is to intravenously replace the deficient blood clotting factor; however, some individuals may develop antibodies to this replacement factor. This study will evaluate the effectiveness of rituximab at reducing the antibodies that develop in response to the replacement factor in individuals with severe hemophilia A.
Interventions
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-06 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00331006
The ClinicalTrials.gov registry entry for NCT00331006 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carelon Research, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rituximab is the first listed.
NCT00331006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00331006 about?
NCT00331006 is a clinical study titled "Rituximab to Treat Severe Hemophilia A". Hemophilia A is a serious blood clotting disorder caused by a lack of factor VIII, a specialized protein needed for normal blood clotting to occur. Individuals with this disease may experience spontaneous bleeding, pain and swelling in their joints due to excess bleeding, and bruising. A common trea...
What is the current status of trial NCT00331006?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2006-06. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00331006?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00331006?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.